title: Hepatic Fas protein expression might be a predictive factor for hepatocellular carcinoma development in patients with chronic hepatitis C undergoing interferon therapy.
abstract: BACKGROUND
  Several studies have revealed that interferon treatment may reduce the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV). However, even after eradication of HCV, patients remain at risk for developing HCC.
  
  
  METHODS
  Of 153 consecutive HCV patients who were treated with interferon and followed up for 5 years, 17 (11.1%) developed HCC. To elucidate predictive factors of HCC development, multivariate analysis was done for the 153 patients, and Fas protein expression in the biopsied specimens of liver before interferon treatment was examined in 17 patients who developed HCC and 17 patients who did not.
  
  
  RESULTS
  Among the independent factors (sex, age, HCV genotype, HCV-RNA level, effect of interferon therapy, serum alanine aminotransferase before interferon therapy, and histologic stage and grade) tested by Cox proportional-hazards analysis, histologic stage (hepatic fibrosis) before interferon was significantly associated with HCC development (p = 0.01). In addition, the intensity of Fas protein expression was significantly greater in the liver specimens of the patients who developed HCC than in those who did not (p = 0.015).
  
  
  CONCLUSIONS
  Histologic stage (hepatic fibrosis) and Fas protein expression before interferon treatment might be indicative of the need for intensive follow-up in patients with chronic hepatitis C undergoing interferon therapy.
authors.affiliation: Department of Gastroenterology, Chukyo Hospital, Nagoya City University, Nagoya, Japan.
authors.forename: Noboru
authors.initials: N
authors.lastname: Hirashima
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Tomoyoshi
authors.initials: T
authors.lastname: Ohono
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Kimura
authors.forename: Izumi
authors.initials: I
authors.lastname: Hasegawa
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D015870:Gene Expression / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000209:etiology / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009842:Oligopeptides / Q000235:genetics*; D011237:Predictive Value of Tests; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C096131:valyl-glutamyl-isoleucyl-asparaginyl-cysteinyl-threonyl-arginine; D007372:Interferons